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was performed in all patients with RBD and in 11 patients 
with PD. All RBD patients underwent olfactory function 
testing. The likelihood ratio (LR) for prodromal PD was 
calculated for each patient based on published research cri-
teria. Skin serial sections were assessed by double-immu-
nofluorescence labelling with antibodies to pSer129-alpha-
syn under blinded conditions. P-alpha-syn was visualized 
in 10/18 patients with RBD (sensitivity of 55.6%) and in 
20/25 early PD patients (sensitivity of 80%) but in none of 
the controls (specificity of 100%). The percentage of der-
mal structures innervated by p-alpha-syn-positive fibres 
was negatively correlated with dopamine transporter bind-
ing in the FP-CIT-SPECT (ρ = −0.377, p = 0.048), with 
olfactory function (ρ = −0.668, p = 0.002), and posi-
tively correlated with the total LR for RBD to present pro-
dromal PD (ρ = 0.531, p = 0.023). Dermal p-alpha-syn 
can be considered a peripheral histopathological marker 
of synucleinopathy and can be detected in a subgroup of 
RBD patients presumably representing prodromal PD. Der-
mal p-alpha-syn is detectable in RBD patients without PD 
motor symptoms, thereby stratifying a patient group that is 
of great interest for clinical trials testing disease-modifying 
drugs.
Keywords REM sleep behaviour disorder · Parkinson’s 
disease · Alpha-synuclein · Skin biopsy · FP-CIT-SPECT
Introduction
Parkinson’s disease (PD), like other neurodegenerative dis-
orders, does not start suddenly, but progresses through early 
“prodromal” stages, in which the defining motor symptoms 
have not yet emerged. This poses an important obstacle 
in clinical research for disease-modifying therapies, as 
Abstract Phosphorylated alpha-synuclein (p-alpha-syn) 
deposits, one of the neuropathological hallmarks of Parkin-
son’s disease (PD), have recently been detected in dermal 
nerve fibres in PD patients with good specificity and sensi-
tivity. Here, we studied whether p-alpha-syn may serve as 
a biomarker in patients with a high risk of developing PD, 
such as those with REM sleep behaviour disorder (RBD). 
We compared the presence and distribution of p-alpha-syn 
deposits in dermal nerve fibres in 18 patients with RBD, 25 
patients with early PD and 20 normal controls. Skin biopsy 
was taken at C7, Th10, and the upper and lower leg. Presyn-
aptic dopamine transporter imaging using FP-CIT-SPECT 
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PD only becomes clinically obvious when patients have 
already lost 80% of dopaminergic nerve terminal function 
in the posterior putamen [24, 27] and an estimated 30–50% 
of nigral dopaminergic neurons have died [11]. A defi-
nite diagnosis of PD is based on pathologic confirmation 
of alpha-synuclein containing Lewy bodies and dopamine 
neuronal loss in the substantia nigra pars compacta with a 
pre-mortem history of Parkinsonism, but this “gold stand-
ard” is only established after death.
We and others have recently proposed that histopatho-
logical confirmation of PD may be advanced by pre-mor-
tem biopsies demonstrating phosphorylated Ser129-alpha-
synuclein (p-alpha-syn) deposition within neurons and 
neurites of the enteric nervous system, the submandibular 
gland, or the skin, closely resembling the central nervous 
system pathology [5, 6, 8, 20, 26, 39]. Skin biopsies are 
particularly easy to perform. Peripheral p-alpha-syn pathol-
ogy within dermal nerve fibres has proven to have high sen-
sitivity and specificity in differentiating PD from tauopa-
thies or other atypical forms of Parkinsonism [6, 8, 10].
So far, dermal p-alpha-syn deposition has only been 
studied in patients with clinically manifest, i.e. motor PD. 
It is unknown if dermal nerve fibres become involved in the 
disease process during premotor stages and how they relate 
to other markers of prodromal PD. In this study, we address 
the potential value of dermal p-alpha-syn deposition as a 
premotor histopathological biomarker of PD by evaluat-
ing skin biopsies in patients with REM sleep behaviour 
disorder (RBD), a well-established clinical non-motor risk 
marker of PD [16, 18]. Patients with RBD have an approx-
imately 85% risk of conversion into a clinically manifest 
alpha-synucleinopathy [dementia with Lewy bodies (DLB), 
PD or multiple system atrophy (MSA)] within 15-20 years, 
among which PD and DLB are the most frequent [16, 18, 
23]. Accordingly, neuropathological studies of patients 
with RBD have revealed the presence of Lewy bodies in 
the brainstem [3, 16, 37].
By combining a diagnosis of RBD with other clinical 
non-motor signs of neurodegenerative alpha-synucleinopa-
thies, such as olfactory dysfunction and neuroimaging of 
impaired dopamine transporter ligand binding (i.e. 123I-N-
ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)tro-
pane single photon emission computed tomography, FP-
CIT-SPECT), one can define a subgroup of patients with 
a high probability of conversion to motor Parkinsonism 
within a few years [17, 22]. Using probability methodol-
ogy, research criteria for prodromal PD have been proposed 
as a hypothetical concept by the International Parkinson 
and Movement Disorder Society (MDS) [2] for validation 
and updating in future studies, as recently employed in a 
cohort of elderly people [21].
In this case control study, we compare the presence and 
extent of dermal p-alpha-syn depositions in patients with a 
high risk of prodromal PD, i.e. RBD patients, with early 
motor stages of PD and healthy controls.
Materials and methods
The study was approved by the ethic’s committees of the 
Universities of Würzburg and Marburg, Germany. All 
patients and controls gave written informed consent to 
participate.
Patients and controls
20 patients with idiopathic RBD who attended the Depart-
ment of Neurology, University Marburg, Marburg, Ger-
many, for diagnostic work-up were prospectively recruited 
between December 2014 and July 2016. Two of these 
patients were later excluded, one because of suspected sec-
ondary (medication-induced) RBD that completely remit-
ted, and one who turned out to have developed MSA at 
the time of skin biopsy. Consequently, 18 patients were 
finally included in our study. 25 patients with PD Hoehn 
and Yahr (H&Y) stages 1 and 2 [14] were prospectively 
recruited from the Departments of Neurology at the Uni-
versity Hospitals Marburg and Würzburg during the same 
time period. Skin biopsies were obtained from the patients’ 
spouses without clinical symptoms of PD or RBD as con-
trols for p-alpha-syn detection (n = 20). RBD patients were 
diagnosed by medical history followed by video-polysom-
nography according to the consensus criteria of the Interna-
tional RBD Study Group [31] and to the International Clas-
sification of Sleep Disorders (version 3) [25]. Patients with 
PD were diagnosed according to the United Kingdom Brain 
Bank criteria [15] and staged according to Hoehn and Yahr 
[14]. The severity of motor symptoms was assessed in RBD 
and PD patients using the Unified Parkinson’s Disease Rat-
ing Scale (UPDRS) part 3 [13] and non-motor symptoms 
were measured by the German version of the non-motor 
symptom scale [36]. The RBD screening questionnaire 
(RBD-SQ) was employed for the subjective reporting of 
RBD related symptoms in the RBD group [34]. The Beck 
Depression Inventory (BDI) was applied for assessment of 
depressive symptoms [1], the Montreal Cognitive Assess-
ment (MOCA) for testing of cognitive function [28].
Assessment of olfaction
Olfaction was assessed in all RBD patients, but not in PD 
patients and controls, by means of the standardized Snif-
fin’ Sticks test as described previously [33]. The bilateral 
olfactory threshold, odour identification and odour dis-
crimination were investigated with three separate sub-
tests. The scores of threshold (T), discrimination (D) and 
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identification (I) were summed and the combined value 
(TDI) categorized into five defined stages: anosmia (TDI 
score ≤15), severe hyposmia (16–20), moderate hyposmia 
(21–25), mild hyposmia (26–30), and normosmia (TDI 
>30).
123I‑FP‑CIT SPECT
In all RBD patients and 11 PD patients the presynaptic 
density of nigrostriatal terminals was visualized and quan-
tified by SPECT and the dopamine transporter tracer N-ω-
fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)tropane 
([123I]FP-CIT). Before injection of 185 MBq [123I]FP-CIT, 
the thyroid gland was blocked with sodium perchlorate. 
Scans were acquired on a dual-headed gamma camera 
(RBD patients: Symbia S; PD patients: Symbia T2; Sie-
mens, Erlangen, Germany) 180 min after injection, a time-
point at which the specific striatal to non-specific binding 
ratios are stable for several hours [4]. The images were 
obtained in 120 projections over a 360° arc by means of 
the step-and-shoot mode with a 40 s acquisition time per 
projection. Transverse reconstructed slices were generated 
as previously reported [40].
All scans, apart from one where no raw data were avail-
able, were analysed with Brain Analysis Software (BRASS 
version PDR 2.5; Hermes Medical Solutions, Sweden) 
(n = 28; 17 RBD, 11 PD). The RBD patient for whom 
no raw data were available showed a reduction of striatal 
dopamine transporter binding, particularly in the puta-
men, but the data were not included in the calculation of 
the correlation between FP-CIT-SPECT data and dermal 
p-alpha-syn deposition due to a lack of comparability. In 
the Brain Analysis Software, the individual patient images 
were automatically coregistered to a template generated 
from [123I]FP-CIT scans obtained in healthy controls from 
the ENC-DAT study [38]. On this template, volumes of 
interest (VOIs) were defined for each caudate nucleus and 
each putamen bilaterally, and a large VOI for the occipi-
tal cortex (reference region). For each individual, average 
counts (total binding) for all voxels within the VOIs were 
calculated. The specific to non-specific binding ratio was 
used as the outcome measure and calculated as follows: 
(total binding in right caudate and left caudate nucleus or 
right putamen and left putamen − non-specific binding)/
non-specific binding. Since the striatal [123I]FP-CIT bind-
ing declines by natural ageing, all values were corrected 
for age. For each study participant an age-corrected ratio 
lower than two SD from the mean of controls [n = 24; age-
range 18–73 years, obtained from the ENC-DAT study (see 
above)] was defined as an abnormal, i.e. reduced specific 
to non-specific binding ratio. The lowest normal (cut-off)
value was determined to be 2. For quantitative comparison 
and correlation analysis, the lowest putaminal value was 
used.
Likelihood of prodromal PD
The MDS has recently proposed a method to calculate 
the likelihood of prodromal PD [2]. In this hypothetical 
concept, the authors selected risk markers and prodromal 
markers for PD based on a literature review. The likelihood 
ratio (LR) of each of these markers is calculated from its 
sensitivity and specificity as described in the literature. 
The total LR of a patient is obtained by multiplying the LR 
of all available risk and prodromal markers. The post-test 
probability can be calculated based on the age-dependent 
prior probability of each patient to develop PD and the total 
LR. The criteria of prodromal PD are based on the age-
dependent prior probability and the total LR of a patient. 
For all RBD patients in our study, the total LR and the post-
test probability were calculated, and we checked if the cri-
teria of prodromal PD were fulfilled or not.
Skin biopsy and immunofluorescence
Skin biopsies with a diameter of 5 mm were taken from 
four biopsy sites per person, namely from the back (C7 and 
Th10, paravertebral skin) and from the proximal (10 cm 
below the trochanter) and distal leg (10 cm above the lateral 
malleolus), under local anaesthesia as previously described 
[8]. The biopsy was taken from the right side in all patients 
and controls except for two RBD patients and one control 
who had the biopsy on the left side. No side effects of the 
biopsy procedure were reported. All samples were fixed 
with 4% paraformaldehyde for 30 min and cryopreserved 
until use. 50 serial sections of 20-µm thickness were cut 
from each biopsy and every tenth section was analysed. 
Thus, a total number of five sections per biopsy site and 20 
sections per patient were evaluated. Section thickness was 
chosen based on previous studies showing that thicker sec-
tions resulted in a weaker staining. Double-immunofluores-
cence with antibodies to PGP9.5 (axonal marker, Zytomed 
Systems, Berlin, Germany, 1:1000) and to alpha-synuclein 
phosphorylated at Serine 129 (clone P-Syn/81A, Covance, 
Princeton, New Jersey, USA, 1:500) and appropriate Alex-
aFluor488- and Cy3-conjugated secondary antibodies was 
performed. The sections were evaluated using a fluores-
cence microscope (Ax10, Zeiss, Oberkochen, Germany) 
with a CARVII-system and Visiview software (Visitron 
GmbH, Puchheim, Germany). Images were digitized using 
the confocal microscope Olympus IX81 (Olympus, Tokyo, 
Japan) with Fluoview Olympus Software FV10-ASW4.1. 
Maximum projections of z stacks were performed using 
Image J. Biopsies were classified as positive if at least 
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one dermal nerve fibre was p-alpha-syn-immunoreactive. 
Patients were considered as positive if at least one biopsy 
site showed p-alpha-syn-immunoreactive nerve fibres. The 
number of positive biopsy sites per patient was recorded. 
Additionally, the number of dermal autonomic structures 
(sweat glands, blood vessels, erector pilorum muscles) and 
dermal nerve bundles per biopsy was counted and the per-
centage of structures innervated by p-alpha-syn-positive 
nerve fibres was calculated as previously described [7]. The 
average of all four biopsy sites was used for group compar-
isons and correlation analysis. Evaluation of sections was 
performed under blinded conditions, as the examiner had 
no information about the underlying diagnosis (RBD, PD 
or control), the result of the FP-CIT-SPECT, or of the olfac-
tory function test.
Statistical evaluation
SPSS Statistics 23 software (IBM, Ehningen, Germany) 
was used for statistical analysis, GPower 3.1 (University 
of Düsseldorf, Germany) was used for sample size calcu-
lation. Sample size calculation was based on the primary 
hypothesis that p-alpha-syn is more often detectable in 
patients with RBD compared to normal controls. A ratio 
of proportions of positive cases of 45 to 1 was assumed 
as effect size based on previous studies on p-alpha-syn in 
PD and the assumption that about 80% of all RBD patients 
convert to PD [8]. For the application of two-sided Fisher’s 
exact test with a significance level of 0.05 and a power of 
0.9, a sample size of at least 17 for each group was con-
sidered necessary. Numerical data were tested for normal 
distribution using the Kolmogorov–Smirnov test and turned 
out not to be normally distributed. Therefore, for com-
parison of numerical data the two-tailed non-parametric 
Kruskal–Wallis test and Mann–Whitney U test were used. 
Categorical data were tested by two-sided Fisher’s exact 
test. Two-sided Spearman’s rank correlation test was used 
for correlation analysis. A nominal significance level of 
5% was applied. As this is an exploratory study, to avoid a 
decrease of power and missing of possibly important find-
ings, we did not adjust for multiple comparisons [30].
Results
Patients
Demographic data and symptom scores of all patients and 
controls are summarized in Table 1 and in the Supplemental 
Table. Age did not differ between groups, there were more 
females in the control than in the RBD group (p = 0.009), 
but gender distribution did not significantly differ between 
RBD and PD patients.
Detection of p‑alpha‑syn in dermal nerve fibres in RBD
P-alpha-syn was detected in dermal nerve fibres of 10/18 
(55.6%) patients with RBD, in 9/13 patients (69.2%) with 
PD H&Y stage I, and in 11/12 patients (91.7%) with PD 
H&Y stage II, but not in any of 20 normal controls (Figs. 1, 
2). P-alpha-syn immunoreactivity was found within der-
mal nerve fibres, resembling Lewy neurites that are known 
from brain tissue (Fig. 1). Thus, p-alpha-syn was detected 
more frequently in patients with RBD or PD compared to 
controls (RBD vs controls: p = 0.0001, PD vs controls: 
p = 0.0001) with a sensitivity of 55.6% in RBD and 80% 
in PD and a specificity of 100%. The median number of 
p-alpha-syn deposits and the median percentage of dermal 
structures innervated by p-alpha-syn-positive fibres are 
given in Table 1. Most p-alpha-syn-positive dermal nerve 
fibres were autonomic fibres around blood vessels (six 
RBD patients, 18 PD patients, Fig. 2a, b), erector pilorum 
muscles (one RBD patient, four PD patients, Fig. 2e, f) or 
sweat glands (two RBD patients, six PD patients, Fig. 2g, 
h). Fibres within dermal nerve bundles not attached to a 
certain autonomic structure were affected in all ten p-alpha-
syn-positive RBD patients and 12 PD patients. P-alpha-syn 
was found in somatosensory nerve fibres of the subepider-
mal plexus in four patients with RBD and in three patients 
of the PD group (Fig. 2c, d) (Supplemental Table). In two 
patients with RBD only somatosensory nerve fibres were 
affected, in two RBD patients, autonomic and somatosen-
sory fibres were positive. In all three patients with PD and 
involvement of somatosensory subepidermal nerve fibres, 
autonomic fibres were involved as well. In summary, over-
all fibre type involvement in RBD was similar to PD.
In the ten p-alpha-syn-positive RBD patients, most 
p-alpha-syn-positive nerve fibres were found in biopsies of 
the neck and back (C7, five patients; Th10, eight patients), 
fewer in the legs (proximal leg: three patients, distal leg: 
five patients). In the 20 p-alpha-syn-positive PD patients, 
there was a trend of more p-alpha-syn-positive fibres to be 
found in the periphery (distal leg, 12 patients; proximal leg, 
11 patients; Th10, 10 patients and C7, 8 patients); however, 
the differences of affected biopsy sites were not significant 
(Supplemental Table).
Negative correlation between dopamine transporter 
binding and dermal p‑alpha‑syn deposition
FP-CIT-SPECT was performed in all 18 patients with RBD 
and in 11 patients with PD and revealed diminished stri-
atal dopamine transporter binding in 10/18 patients with 
RBD and in all patients with PD (Fig. 3a). Eight patients 
with RBD showed normal striatal dopamine transporter 
binding ratios above the cut-off value of two in the left and 
right putamen. Of the ten RBD patients with diminished 
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dopamine transporter binding seven showed deposition 
of p-alpha-syn in the skin biopsy (Fig. 3a). On the other 
hand, seven of ten RBD patients with p-alpha-syn in the 
skin biopsy showed a reduced striatal dopamine transporter 
binding, whereas three of the p-alpha-syn-positive RBD 
patients had a normal FP-CIT-SPECT. Of these three 
patients, one patient’s dopamine transporter binding in the 
putamen was just above the cut-off value of 2 (2.04), the 
Table 1  Overview of demographic data, clinical scores and p-alpha-syn deposition (number of sites and percentage of structures positive for 
p-alpha-syn) of patients with RBD, PD and normal controls
BDI Beck Depression Inventory, FP-CIT-SPECT 123I-2beta-carbomethoxy-3beta-(4-iodophenyl)-N-(3-fluoropropyl)-nortropane Single photon 
emission computed tomography, NMS non-motor symptom score, p-alpha-syn phosphorylated alpha-synuclein, PD Parkinson’s disease, RBD 
REM sleep behaviour disorder, RBD-SQ RBD screening questionnaire, UPDRS Unified Parkinson’s Disease Rating Scale
RBD with normal FP-CIT-
SPECT
RBD with pathological FP-
CIT-SPECT
PD Healthy controls
Number (n), gender (male/
female)
8; 6 male, 2 female 10; 9 male, 1 female 25; 14 male, 11 female 20; 8 male, 12 female
Median age (years) (quartiles) 62 (57.75/69.25) 65 (59.5/66.75) 63 (59/67) 59 (52/69)
Median RBD-SQ (quartiles) 10 (8.75/10.5) 10 (7.5/10) – –
Median MoCA (quartiles) 28 (26.5/29.5) 26 (24.75/28.25) – –
Median BDI (quartiles) 16 (12.75/20.25) 8·5 (2.75/17.5) – –
Patients with p-alpha-syn 
deposition
3 (37.5%) 7 (70%) 20 (80%) 0
Median percentage of p-alpha-
syn-positive structures 
(quartiles)
0 (0/6.10) 2.25 (0.15/6.16) 3.67 (1.63/7.00) 0
Median number of p-alpha-
syn-positive biopsy sites 
(quartiles)
0 (0/2) 1 (0.25/2.5) 2 (1/3) 0
Median duration of RBD 
(years) (quartiles)
3.5 (1.95/6.25) 5.5 (3.75/7.75) – –
Median UPDRS 1 (quartiles) 3 (1/5.75) 2.5 (1.75/4) 4.5 (4/8) –
Median UPDRS 2 (quartiles) 1 (0.25/2.5) 0 (0/1) 4 (3/4) –
Median UPDRS 3 (quartiles) 2.5 (0.75/4.75) 1 (0/2.75) 19 (11.75/21.25) –
Median NMS (quartiles) 10 (7.5/11.75) 8 (4.5/12.5) 28 (14/33) –
Median TDI (quartiles) 23.88 (14.88/30.25) 12 (6/23.94) – –
Fig. 1  Immunofluorescence staining with anti-p-alpha-syn (red) 
and anti-PGP9.5 (green,  c). Dermal p-alpha-syn deposition was 
found within axons of somatosensory or autonomic nerve fibres (b) 
and resembled Lewy neurites that are typically found in the CNS 
(a). Lewy bodies as seen in CNS tissue (a, arrow) are not detecta-
ble in skin biopsies as the cell bodies of somatosensory neurons are 
located in the dorsal root ganglia and sympathetic ganglia. P-alpha-
syn immunoreactivity forms a punctuated line within the nerve fibres. 
c illustrates the localization of p-alpha-syn deposition within a nerve 
fibre of a dermal nerve bundle. Scale bar 10 µm p-alpha-syn phos-
phorylated alpha-synuclein
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other patients showed a dopamine transporter binding of 
2.58 and 2.31 (Fig. 3a, lower panel).
The median percentage of dermal structures innervated 
by p-alpha-syn-positive fibres was not significantly differ-
ent in patients with PD compared to RBD patients with 
normal or pathological FP-CIT-SPECT. However, there 
was a trend to a higher percentage in iPD (3.67) than in 
RBD with (2.25) and without (0) pathological FP-CIT-
SPECT (Fig. 3a, upper panel).
The lowest putaminal value of the FP-CIT-SPECT in 
the RBD patients (n = 17; one patient without raw data, 
thus not included in this analysis) was inversely correlated 
with the percentage of dermal structures innervated by 
p-alpha-syn-positive nerve fibres (ρ = −0.38, p = 0.048) 
and the number of biopsy sites with p-alpha-syn deposition 
(ρ = −0.40, p = 0.037). The lowest putaminal FP-CIT-
SPECT value tended to be lower in patients with p-alpha-
syn deposition compared to patients without p-alpha-syn 
deposition in the skin biopsy, but the difference failed to 
reach significance (p = 0.2, Fig. 3a, lower panel).
Negative correlation between olfactory function 
and dermal p‑alpha‑syn deposition in RBD
Olfactory function was evaluated in all patients with RBD, 
resulting in a median TDI of 16.4 (range 0–35.75). Olfac-
tory dysfunction could be diagnosed in 15/18 patients 
(83·3%), further categorized as anosmia (TDI <15) in 
eight patients, severe hyposmia (TDI 16–20) in three 
patients, mild hyposmia (TDI 26–30) in four patients. All 
eight patients with anosmia and two of three patients with 
severe hyposmia displayed p-alpha-syn deposition in the 
skin biopsies; however, there was no p-alpha-syn deposi-
tion in the four patients with mild hyposmia or the three 
patients with normal olfactory function. P-alpha-syn dep-
osition was inversely correlated with olfactory function 
(number of positive biopsy sites and TDI: rho = −0.64 
p = 0.004, percentage of positive dermal structures and 
TDI: rho = −0.67, p = 0.002). The number of p-alpha-syn-
positive biopsy sites and the percentage of p-alpha-syn-
positive structures was higher in anosmic, severe or moder-
ate hyposmic RBD patients compared to mildly hyposmic 
or normosmic patients (p = 0.0001, Fig. 3b, upper panel), 
and patients with p-alpha-syn deposition in the skin biopsy 
had lower TDI values (p = 0.0001, Fig. 3b, lower panel).
Positive correlation between p‑alpha‑syn deposition 
and likelihood of prodromal PD
Based on the research criteria of the MDS, the LR of 14 of 
18 RBD patients fulfilled the criteria for prodromal PD [2]. 
Dermal p-alpha-syn was found in ten patients who fulfilled 
the criteria and not in the four patients whose LR was below 
the age-dependent cut-off value. The LR and the post-test 
probabilities of prodromal PD correlated with the number 
of positive biopsy sites (total LR: ρ = 0.51, p = 0.032, 
Fig. 2  Confocal photomicrographs of double-immunofluorescence 
with anti-p-alpha-syn (red) and anti-PGP 9.5 (axonal marker, green). 
P-alpha-syn -immunoreactive nerve fibres can be found in vasomotor 
nerve fibres around vessels (a, b), in somatosensory nerve fibres of 
the subepidermal plexus (c, d), in pilomotor nerve fibres of erector 
pilorum muscles (e, f) and in sudomotor fibres around sweat glands 
(g, h). Scale bar 20 µm. p-alpha-syn phosphorylated alpha-synuclein
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post-test probability: ρ = 0.55, p = 0.019) and the per-
centage of dermal structures with p-alpha-syn-positive 
fibres (total LR: ρ = 0.53, p = 0.023, post-test probabil-
ity: ρ = 0.57, p = 0.019). The percentage of p-alpha-syn-
positive dermal structures and the number of p-alpha-syn-
positive biopsy sites was higher in patients who fulfilled the 
research criteria for prodromal PD (p = 0.035, Fig. 3c) and 
p-alpha-syn-positive RBD patients had a post-test probabil-
ity of (p = 0.009, Fig. 3c, lower panel).
Discussion
The present study provides evidence of p-alpha-syn depo-
sition in dermal nerve fibres of patients with RBD, which 
is often a prodromal stage of a synucleinopathy, mostly 
PD or DLB. We show a high probability (10/11 patients 
with moderate or severe hyposmia) of dermal p-alpha-syn 
deposition in RBD patients with olfactory dysfunction, 
Fig. 3  Box plots  illustrating skin biopsy, FP-CIT-SPECT, LR and 
TDI data. The box plots of the upper panels a–c illustrate the median 
percentage of p-alpha-syn-positive dermal nerve structures per patient 
(y-axis) in patients with abnormal/normal FP-CIT-SPECT (a), nor-
mosmic (TDI > 26)/hyposmic (TDI ≤ 26) patients (b) and patients 
fulfilling/not fulfilling the research MDS criteria of prodromal PD 
(x-axis) (c). In a, upper panel, PD patients are included, all other pan-
els only represent the RBD group. The black line marks the median, 
the box represents the quartiles, the whiskers mark the range. Indi-
vidual patient values are represented by circles. The percentage of 
p-alpha-syn-positive dermal structures shows a trend towards higher 
numbers in PD, declining from PD to RBD with abnormal, FP-CIT-
SPECT (i.e. reduced specific to non-specific binding ratio) and fur-
ther to RBD with normal FP-CIT-SPECT (a). P-alpha-syn deposition 
is not found in normosmic patients, but is high in hyposmic patients 
(b) and is much more abundant in patients fulfilling the MDS criteria 
of prodromal PD (c). The  box plots of the lower images a–c com-
pare the lowest putaminal FP-CIT-SPECT values, TDI values and the 
probability of prodromal PD (y-axis) in patients without (negative) 
and with (positive) p-alpha-syn deposition in the skin biopsy (x-axis). 
Putaminal FP-CIT-SPECT values tend to be lower in patients with 
at least one p-alpha-syn deposition (positive) vs in patients with no 
deposition (negative) (a). In a the punctate line indicates the lower 
normal value (2.0) of the FP-CIT-SPECT value. TDI values (b) are 
significantly lower in patients with p-alpha-syn deposits in the skin 
biopsy and the probability of prodromal PD is higher in patients 
with p-alpha-syn deposition (c). In a, lower panel, only 17 individ-
ual patient values are represented by circles as the FP-CIT-SPECT 
of one patient was not included into the quantitative analysis due to 
lack of raw data. FP-CIT-SPECT 123I-2beta-carbomethoxy-3beta-
(4-iodophenyl)-N-(3-fluoropropyl)-nortropane single photon emission 
computed tomography, p-alpha-syn phosphorylated alpha-synuclein, 
PD Parkinson’s disease, RBD REM sleep behaviour disorder, TDI 
olfactory threshold, discrimination and identification score
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most of whom also had reduced dopamine transporter 
binding in FP-CIT-SPECT. Our data encourage the use of 
skin biopsy as a histopathological stratification tool for 
clinical studies in RBD and PD patients.
Identification of patients with prodromal PD is of high 
interest for clinical studies with disease-modifying drugs. 
Patients with RBD carry a high risk to convert to PD, 
and therefore comprise a patient group of special inter-
est. According to present knowledge, up to 15% of RBD 
patients will not convert to an alpha-synucleinopathy 
within 15 years [16, 18, 23]. Therefore, stratification tools 
are necessary to identify those RBD patients who suffer 
from an alpha-synucleinopathy as indicated by p-alpha-syn 
deposition and therefore have the highest risk of manifest-
ing motor symptoms. For this purpose, probability crite-
ria, including FP-CIT-SPECT, RBD and hyposmia, were 
introduced by the MDS and are currently validated [2, 21]. 
The present data show a correlation of dermal p-alpha-
syn deposition not only with single items of these criteria 
like reduced dopamine transporter binding in the FP-CIT-
SPECT and hyposmia, but also with the probability score 
in total. Thus, p-alpha-syn deposition in dermal nerve 
fibres may be a suitable stratification marker for prodromal 
PD. Additionally, in contrast to FP-CIT-SPECT and other 
potential measures of prodromal PD, skin biopsy provides 
direct histopathological evidence of p-alpha-syn and may 
therefore be of particular interest in clinical studies target-
ing p-alpha-syn deposition. Patients combining abnormal 
FP-CIT-SPECT and p-alpha-syn deposition in the skin may 
represent a group of even higher interest for these clinical 
trials.
In RBD, dermal p-alpha-syn deposition was detected 
with a frequency of 55.6% and correlated with other risk 
markers of PD development as displayed by the total LR 
and the post-test probability of prodromal PD as pro-
posed by the MDS. It needs to be emphasized that RBD 
is included in the calculation of the total LR. For a gen-
eral conclusion on the association between prodromal PD 
according to these research criteria and p-alpha-syn deposi-
tion, studies including cases of prodromal PD without RBD 
would be needed.
The sensitivity of p-alpha-syn detection in skin biop-
sies of RBD patients may be influenced by the disease 
stage of RBD: our cohort comprises a relatively large per-
centage of RBD patients with abnormal FP-CIT-SPECT 
indicating the conversion to motor PD. Larger, preferen-
tially multicentre studies are needed to determine the sen-
sitivity of dermal p-alpha-syn deposition in RBD patients 
of different stages of disease. Our data show that dermal 
p-alpha-syn can be detected prior to the onset of motor 
symptoms and may indicate a high risk of conversion to 
motor PD. Hyposmia is supposed to occur approximately 
5 years before conversion of patients with RBD to motor 
PD [29], and FP-CIT-SPECT is considered a progressive 
marker for the risk of conversion of patients with RBD 
to PD [19]. To determine the exact time-point of dermal 
p-alpha-syn deposition in relation to the onset of manifest 
PD will require longitudinal studies. In our investigated 
cohort of RBD patients, p-alpha-syn deposition was present 
in almost all patients with severe hyposmia and in most 
patients with reduced dopamine transporter binding in the 
FP-CIT-SPECT. In three patients, however, the deposition 
of p-alpha-syn in the skin was associated with a normal FP-
CIT-SPECT, i.e. it occurred before the development of a 
premotor dopaminergic nigrostriatal dysfunction. Whether 
a higher proportion of RBD patients with a normal FP-CIT-
SPECT than in our cohort already have dermal p-alpha-syn 
deposits remains to be demonstrated. If this were the case, 
dermal p-alpha-syn deposits might be an earlier indicator 
of future conversion to clinical PD than FP-CIT-SPECT. 
On the other hand, RBD patients with a normal FP-CIT-
SPECT, normosmia, and a negative finding for p-alpha-syn 
in skin biopsy (n = 6) may either represent a stage where 
conversion into PD is not yet detectable, or may belong to 
the approximately 15% RBD patients who will not convert. 
In contrast to PD where no stage-dependent differences 
of p-alpha-syn deposition was found in previous studies, 
our data show that p-alpha-syn deposition increases with 
advanced stages of RBD as represented by olfactory dys-
function and abnormal FP-CIT-SPECT. A testable hypoth-
esis would be that dermal p-alpha-syn spreading occurs 
during the course of RBD and does not further increase at 
the stage of motor PD.
By taking biopsies from four different sites and perform-
ing serial sections, we achieved a moderate sensitivity and 
high specificity of p-alpha-syn detection as a biomarker for 
PD in patients with early PD (Hoehn and Yahr stage I–II; 
sensitivity of 80%, specificity of 100%). Sensitivity and 
specificity of p-alpha-syn as a biomarker of PD at the onset 
of motor symptoms does not appear to differ from later 
stages of the disease that were assessed in previous studies 
[6, 8]. However, sensitivity and specificity differs between 
studies [6, 8, 10, 12, 26, 41], presumably due to different 
protocols, biopsy sites and number of sections analysed [9]. 
We show that serial cryosections and multiple biopsy sites 
increase sensitivity. Detailed comparative methodological 
studies need to be performed to develop the best possible 
protocol for this method. In contrast to previous studies, we 
could not find a significant decrease of p-alpha-syn deposi-
tion from proximal to distal biopsy sites; however, the sam-
ple size is too low to draw any conclusion from that.
Consistent with an early involvement of the periph-
eral autonomic system in PD, p-alpha-syn deposition 
has recently been reported in gastric and enteric biopsies 
of premotor PD and in colon biopsies of patients with 
RBD [32, 35]. Results were inconsistent with moderate 
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sensitivity and low specificity in the study on prodromal 
PD [35] and low sensitivity but high specificity in the 
study on RBD patients [32], thus not allowing any con-
clusion on the usefulness of enteric biopsies as a strati-
fication tool for RBD patients. A recent study evaluating 
p-alpha-syn deposition in submandibular salivary gland 
biopsies of RBD patients showed a promising high sen-
sitivity and specificity of p-alpha-syn detection, but also 
had a procedural limitation as less than half of the biop-
sies of the RBD patients contained glandular parenchyma 
[39]. In comparison with enteric biopsies and submandib-
ular gland biopsy, skin biopsy appears to be a reasonable 
stratification tool to identify RBD patients with a high 
risk of conversion to PD, as it is technically easy to per-
form and provides a high specificity.
As in former studies, we found p-alpha-syn deposits 
mainly in autonomic fibres in patients with RBD [6, 8]. 
Similarly, in PD unmyelinated somatosensory dermal 
nerve fibres harbour p-alpha-syn deposits less frequently 
than autonomic fibres [6, 8, 10]. In contrast, somatosen-
sory fibres were the major fibre type affected in patients 
with multiple system atrophy [10]. The detection of 
p-alpha-syn in somatosensory dermal nerve fibres in three 
patients with RBD in the present study provides evidence 
that somatosensory nerve fibres are also involved at pre-
motor stages.
A limitation of our study is the lack of longitudinal data. 
A major question that remains to be answered is the out-
come of the eight patients who did not harbour p-alpha-syn 
deposition in their skin biopsies. Three out of these eight 
patients had a reduced nigrostriatal dopamine transporter 
ligand binding in FP-CIT-SPECT, whereas the remaining 
five patients presented a normal FP-CIT-SPECT (Fig. 3a, 
lower panel). Whether the three patients with an already 
affected nigrostriatal dopamine system or all of the eight 
patients will develop PD/DLB or multiple system atrophy 
or whether some or all of them belong to the small percent-
age of patients with RBD who do not develop a synucle-
inopathy will be the subject of longitudinal studies that 
need to follow. Large multicentre longitudinal studies also 
need to be performed to study the temporal relationship 
between dermal p-alpha-syn deposition and conversion to 
PD.
In summary, our study provides evidence that phospho-
rylated alpha-synuclein deposition is present in dermal 
nerve fibres in a subgroup of patients suffering from RBD. 
Considering its relation to other risk factors for conversion 
from RBD to PD such as hyposmia and reduced FP-CIT 
dopamine transporter uptake, p-alpha-syn deposition in 
skin may be used in RBD patients as a peripheral histo-
pathological marker of an alpha-synucleinopathy, prior to 
the onset of PD motor symptoms. Given the simple access 
to skin biopsy and its high specificity, the method may 
assist in future stratification of RBD patient cohorts for 
clinical trials testing disease-modifying drugs.
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